VINCENT TAM to Mice
This is a "connection" page, showing publications VINCENT TAM has written about Mice.
Connection Strength
0.613
-
Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii. Diagn Microbiol Infect Dis. 2025 Nov; 113(3):116991.
Score: 0.068
-
Mechanisms of gelofusine protection in an in vitro model of polymyxin B-associated renal injury. Am J Physiol Renal Physiol. 2024 07 01; 327(1):F137-F145.
Score: 0.063
-
Eicosanoid-Activated PPARa Inhibits NF?B-Dependent Bacterial Clearance During Post-Influenza Superinfection. Front Cell Infect Microbiol. 2022; 12:881462.
Score: 0.056
-
The impact of serum protein binding on bacterial killing of minocycline. J Glob Antimicrob Resist. 2020 06; 21:252-254.
Score: 0.046
-
Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosa. Microbiol Immunol. 2018 Apr; 62(4):291-294.
Score: 0.041
-
The complexity of minocycline serum protein binding. J Antimicrob Chemother. 2017 06 01; 72(6):1632-1634.
Score: 0.039
-
Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. Antimicrob Agents Chemother. 2017 05; 61(5).
Score: 0.039
-
Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 May; 59(5):2720-5.
Score: 0.033
-
Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents. 2013 Dec; 42(6):559-64.
Score: 0.030
-
A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother. 2013 May; 68(5):1104-10.
Score: 0.029
-
Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia model. Antimicrob Agents Chemother. 2011 Oct; 55(10):4601-5.
Score: 0.026
-
Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. J Antimicrob Chemother. 2011 Jun; 66(6):1311-7.
Score: 0.025
-
Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J Infect Dis. 2010 Mar 15; 201(6):889-97.
Score: 0.024
-
In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagn Microbiol Infect Dis. 2009 Aug; 64(4):427-33.
Score: 0.023
-
Systemic exposure to bacterial amyloid curli alters the gut mucosal immune response and the microbiome, exacerbating Salmonella-induced arthritis. Gut Microbes. 2023 Jan-Dec; 15(1):2221813.
Score: 0.014
-
Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans. Antimicrob Agents Chemother. 2019 05; 63(5).
Score: 0.011
-
Co-signaling receptors regulate T-cell plasticity and immune tolerance. Front Biosci (Landmark Ed). 2019 01 01; 24(1):96-132.
Score: 0.011
-
The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques. Antimicrob Agents Chemother. 2017 08; 61(8).
Score: 0.010
-
A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERa protein. Carcinogenesis. 2012 May; 33(5):1089-97.
Score: 0.007
-
Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006 Feb; 50(2):469-73.
Score: 0.004
-
Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006 Jan; 50(1):310-7.
Score: 0.004
-
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis. 2004 Oct 15; 190(8):1464-71.
Score: 0.004
-
Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003 Jul; 112(2):275-85.
Score: 0.004